Endo Squashes N.Y. Allegations That It Falsely Promoted Opioid

Amid the backdrop of the national opioid epidemic, Endo Pharmaceuticals has settled false advertising allegations concerning its promotion of the painkiller Opana ER, according to the New York Attorney General’s Office.

The terms of the deal include a $200,000 penalty and multiple compliance steps to remedy the company’s alleged misrepresentations, according to Attorney General Eric Schneiderman.

Schneiderman’s office contends that the Irish drugmaker “improperly marketed Opana ER as designed to be crush resistant, when Endo’s own studies showed that the pill could be crushed and ground.” Addicts often snort or inject crushed opioid pills.